P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer.
Chrisanthar
Ranjan
R
Knappskog
Stian
S
Staalesen
Vidar
V
Lillehaug
Johan Richard
JR
Lønning
Per Eystein
PE
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D009154:Mutation; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000494:pharmacology / Q000627:therapeutic use*; D011110:Polymorphism, Genetic
D000972:Antineoplastic Agents, Phytogenic; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D017239:Paclitaxel